Objective-Patients with cancer are at an increased risk for venous thromboembolism (VTE). Clotting factor VIII activity (FVIII) has been established as risk factor of primary and recurrent VTE. We investigated FVIII as predictive parameter of VTE in cancer patients.
P atients with malignancy are at high risk to develop venous thromboembolism (VTE). [1] [2] [3] The origin of this procoagulant state in cancer patients is multifactorial 4 and still poorly understood. Pulmonary embolism is a potentially life-threatening complication, especially after cancer surgery. 5 Recently, a scoring system for chemotherapyassociated thrombosis risk was proposed. 6 However, thrombosis prophylaxis in outpatients with cancer is still under debate. More profound knowledge on relevant thrombosis risk factors is needed for a better characterization of the individual thrombosis risk and for the decision on the optimal prophylaxis. 6 -8 Factor VIII (FVIII) plays a key role in the coagulation cascade. On activation by thrombin, factor VIII dissociates from von Willebrand factor and acts as a cofactor to factor IXa in factor X activation, which finally results in accelerated thrombin generation. 9 A high factor VIII activity indicates an increased risk for primary and recurrent venous thromboembolism. 10 -14 High FVIII levels have been observed in patients with multiple myeloma, breast cancer, and colorectal cancer. [15] [16] [17] [18] Data on FVIII as thrombosis risk factor in cancer patients are scarce: in 2006 a small but well-designed retrospective study reported higher FVIII levels in patients with various types of cancer and a history of thrombosis in comparison to a matched control group without thrombosis of the same age, malignancy, stage, site of metastasis, and performance status. 19 In the following year a small prospective study in multiple myeloma patients did not find higher baseline FVIII levels in 14 patients who developed thrombosis during follow-up compared to 121 without consecutive thrombosis. 16 The power of this study was limited by the small sample size. In the present study, we aimed to further elucidate the association between FVIII and the risk of symptomatic VTE in cancer patients.
Methods

Study Design
A cohort of patients with newly diagnosed cancer or progression of disease was analyzed. All patients were participants of the Cancer and Thrombosis Study (CATS), an ongoing prospective cohort study that is performed at the Medical University of Vienna. For this study institutional research ethical approval was received. Participants were informed personally and gave written informed consent. Patients were recruited at the Department of Medicine I and IV, Departments of Surgery, of Radiotherapy and Radiobiology, of Gynecology, of Urology and of Neurosurgery at the Medical University of Vienna between October 2003 and June 2007. Inclu-sion criteria were as follows: (1) patients with newly diagnosed cancer of the brain, breast, lung, upper and lower gastrointestinal tract, pancreas, kidney, prostate, or gynecological system; sarcoma and hematologic malignancies, or progression of disease after complete or partial remission; (2) histological confirmation of diagnosis; (3) age older than 18 years; (4) willingness to participate; and (5) written informed consent. Exclusion criteria for all participants were (1) overt bacterial or viral infection; (2) venous or arterial thromboembolism within the last 3 months; and (3) continuous anticoagulation with vitamin K antagonists or low-molecular-weight heparin (LMWH). Additional exclusion criteria for patients with progression of disease were (4) surgery or radiotherapy (RT) within the last 2 weeks and (5) chemotherapy within the last 3 months. Patients were allowed to take aspirin, ticlopidine, or clopidogrel, and immobilized patients were allowed to be treated with LMWH as thrombosis prophylaxis during their hospital stay. For inclusion in the study all inclusion criteria had to be fulfilled. Patients underwent a structured interview on their medical history. Data on the site of tumor, histology, and tumor stage were documented. Additionally, they received detailed written information on symptoms of VTE and were asked to report immediately to our department in case of developing symptoms. At time of inclusion a blood sample was drawn.
Observation period started at the time of blood sampling. Patients were contacted every 3 months via postal mail or phone to get information about their clinical course regarding occurrence of VTE and anticancer-treatment. Furthermore, their clinical records were examined with respect to the occurrence of any events. In case patients did not respond, their family doctors or relatives were contacted. In case of sudden death, autopsy was aspired. Available autopsy protocols were checked for VTE. Once in a year the Austrian Mortality Registry was searched for entries concerning study participants. The maximum observation time was two years.
Until June 27, 2007 , 956 patients were enrolled, of these 116 were excluded for the following reasons: 57 patients did not match inclusion or exclusion criteria after reevaluation (eg, long-term prophylaxis with LMWH or tumor not confirmed by histology), in 57 patients no complete information on follow up, and in 2 patients no adequate material for laboratory testing were available.
Diagnosis of VTE
Symptomatic or fatal VTE were recorded as event. There was no routine screening for VTE. When a patient developed symptoms of VTE, medical imaging was performed. Diagnosis of VTE was always confirmed by objective methods that were duplex sonography or phlebography for deep vein thrombosis and computerized tomography, ventilation-/perfusion scan, or angiography for pulmonary embolism. In case of a fatal event, diagnosis was confirmed by autopsy. Once a year all events were presented to an adjudication committee that was formed by independent experts in the fields of angiology, radiodiagnostics, and nuclear medicine, who were completely unaware of the laboratory results of the patients. These experts evaluated each event. Incidentally detected thrombotic events (eg, pulmonary embolism detected in a routine computerized tomography) were accepted as end points if the adjudication committee decided that the event was of clinical significance and required continuous anticoagulant treatment. Asymptomatic but clinically significant events that were accepted by the committee as end points are separately mentioned in the results section. Patients who developed VTE were treated with long-term anticoagulation with therapeutic doses of LMWH or with vitamin K antagonists. In case a patient died and an autopsy was performed, and the written protocols were reviewed with regard to the presence of VTE.
Outcome Measures
End points of the study were fatal or symptomatic pulmonary embolism and deep vein thrombosis within 2 years after study inclusion.
Blood Collection and Laboratory Tests
Venous blood samples were collected in Vacutainer K3-EDTA tubes (Vacuette; Greiner-Bio One) and Vacutainer citrate tubes (Vacuette; Greiner-Bio One; containing 1/10 volume sodium citrate stock solution at 0.129 mmol/L) by sterile, atraumatic venipuncture on the day of enrollment. Aliquots of plasma samples were frozen at Ϫ80°C elsius and stored until analysis in series. Factor VIII activity was measured on a Sysmex CA 7000 analyzer using factor VIIIdeficient plasma (Technoclone) and APTT Actin-FS (Dade Behring). The coefficient of variation was 5% to 8%.
Statistical Methods
Metric variables were described by median, 25th and 75th percentile and in some cases additionally minimum and maximum were added. Categorical variables were described by counts and percentages. Group comparisons were performed by Mann-Whitney U test or 2 test when applicable.
Data were analyzed by Cox regression analysis and visualized by Kaplan-Meier curves. Observation end point was fatal or symptomatic VTE. Data were censored at death, at the time of the last patient contact, or after 2 years of follow-up (end of observation). Univariable and multivariable Cox regression analyses were used to calculate risks of VTE for variables of interest: FVIII activity was either entered as logarithmically transformed continuous variable or as categorical variable (above or below the 95th percentile of healthy controls). A logarithm with the base 1.2 was used. The hazard ratio of such a log-transformed metric variable can be interpreted as the risk in/decrease if the log-transformed variable is increased by 20%.
Healthy controls were 75 individuals that were age-and sexmatched to the patients (36 women, 39 men; mean age 61.0, standard deviation 7.6 years). Median factor VIII was 146% (IQR: 126% to 175%), the 95th percentile of FVIII activity in healthy controls was 232%.
Multivariable Cox regression analyses were used to adjust for the covariates age at study inclusion, sex, and treatment regimen (surgery, chemotherapy, and radiotherapy). We assumed that the treatments would influence VTE risk not only until the last day of treatment, but over a prolonged period of time. Therefore, 3 time-dependent binary variables were included in the statistical model that indicated a possible influence by surgery (from the day of surgery plus 6 consecutive weeks), chemotherapy (from the first day of the first treatment cycle until the last day of the last cycle plus 4 weeks), and radiotherapy (from the first day of treatment until the last day plus 4 weeks).
In a second multivariable Cox regression analyses all parameters of the first multivariable analysis plus a variable for tumor type and stage were included. This variable was categorized into 4 levels (0, hematologic malignancies; 1, brain cancer; 2, any cancer but brain cancer and localized disease; 3, any cancer but brain cancer and disseminated disease). Multivariable Cox regression models were tested for all pair-wise interactions and interactions with log(time) by means of candidate variables. Because of the large number of tests, a more stringent probability value of 0.01 was used to indicate statistical significance for these interactions. According to this criterion, age and FVIII have a significant interaction (Pϭ0.0058). Therefore we additionally included this interaction in the multivariable Cox models. Such an interaction implies that the effect of FVIII differs significantly between patients of different age.
A Kaplan-Meier plot was used to visualize the difference in cumulative probability of VTE between patients with a FVIII level above or below the 95th percentile of healthy controls (232%).
Observation time was calculated by reverse Kaplan-Meier procedure.
A probability value of less than 0.05 was determined to indicate statistical significance.
Results
Study Population
Baseline characteristics of the investigated cohort of cancer patients (nϭ840) are given in Table 1 . The cumulative probability of VTE was 6% after 6 months and 8% after 1 year. In total, 62 (7.4%) events were recorded. Eight events (7 PE and 1 internal jugular vein thrombosis) were asymptomatic and detected incidentally on CT scan; they were, however, classified as events, because the adjudication committee considered them to be clinically significant. Characteristics of cancer patients with VTE, site of VTE, classification of cancer, and site of cancer are given in Table 2. FVIII activity showed a right skewed distribution (median 178%, 25th to 75th percentile 136 to 227%, minimum to maximum 51% to 622%). Patients that developed VTE (nϭ62; median F VIII: 211%, IQR: 168 to 257%) had significantly higher factor VIII levels at baseline than those who stayed free of events during follow-up (nϭ778; median: 177%, 25th to 75th percentile 135 to 223%, PϽ0.001). FVIII activity was statistically significantly correlated with age (correlation coefficientϭ0.20; PϽ0.0001) and blood group (correlation coefficientϭ0.15; PϽ0.0001). In multivariable Cox regression analysis the association of FVIII activity with the thrombosis risk was statistically significant and independent of sex and treatment regimen. We observed an interaction between FVIII activity and age: whereas in 40-year-old patients we observed that per factor VIII increase of 20% the VTE risk correspondingly doubled (HRϭ2.0 [95% CI: 1.5 to 2.7], PϽ0.0001), this association was found to be attenuated in older patients (Table 3 ). In a second multivariable analysis a parameter for tumor type and stage was added. Overall tumor type had a statistically significant effect on the thrombosis risk (Pϭ0.04). Patients with any cancer but brain cancer and metastasis had a significantly lower thrombosis risk than those with brain cancer (HRϭ0.4 [95% CI: 0.2 to 0.7, Pϭ0.004]). Other subgroup comparisons of tumor type did not reach statistical significance. The VTE risk did not differ significantly among cancer patients with or without metasta- Figure 1) .
In a subgroup of 667 (79%) patients information on their blood group was available. Distribution of FVIII activity in this subgroup was virtually identical to the whole study population (median 177%, 25th to 75th percentile 137 to 227%, minimum to maximum 51 to 622%). Forty-one percent had blood group A, 36% had 0, 16% B, and 9% AB, respectively. Cancer patients with blood group 0 had a significantly lower factor VIII activity (nϭ240; median: 163%, 25th to 75th percentile 125 to 213, minimum to maximum 51 to 440) than those with blood group A, B, or AB (nϭ426; median: 184%, 25th to 75th percentile 146 to 234, minimum to maximum 56 to 622; PϽ0.001). Further adjustment of the multivariable Cox regression model for blood group had virtually no effect on the calculated hazard ratios for FVIII and VTE: eg, per FVIII increase by 20% the VTE risk increased 2.2-fold in 40-year-old patients (HR 2.2 [95% CI: 1.6 to 2.9], PϽ0.0001) and 1.4-fold in 60-year-old patients (HR 1.4 [95% CI: 1.2 to 1.6], PϽ0.0001).
FVIII differed significantly according to the site of cancer (PϽ0.001, Figure 2 ). In the subgroup of patients with solid malignancies (nϭ627) FVIII was higher in patients with metastasis (medianϭ196, 25th to 75th percentile: 151 to 248) than in those with localized disease (medianϭ163, 25th to 75th percentile: 124 to 198; PϽ0.001) and also a little higher in patients with progression of disease (nϭ387, medianϭ184, 25th to 75th percentile: 144 to 234) than those with newly diagnosed cancer (nϭ453, medianϭ173, 25th to 75th percentile: 130 to 221; Pϭ0.003).
Discussion
In this prospective cohort study we demonstrated that high FVIII plasma level is a significant risk factor for symptomatic VTE in cancer patients. Our data clearly show that the increased risk conferred by FVIII does not depend on a particular cut-off, but that the risk increases continuously and that even small changes of FVIII have a major influence; per FVIII increase of 20% the VTE risk increased by up to 120%. Detailed analyses revealed that high FVIII conferred an especially high risk in younger patients. *Reading advice: A patient with 50 years at study inclusion and a FVIII that is 20% higher than the FVIII level of another 50-year-old patient has a 70% higher risk of venous thromboembolism given that the sex, chemotherapy, surgery and radiotherapy status are the same in both patients.
†The reference population is given in parenthesis. ‡Bold letters indicate statistically significant results. 
Vormittag et al Cancer, Factor VIII, and Thrombosis
Our data are in accordance with studies that reported increased FVIII levels in cancer patients in comparison to healthy individuals. [15] [16] [17] [18] More than 20% of patients in our cohort had FVIII levels above the 95th percentile of the normal population. The origin of these high plasma FVIII levels is not fully understood. We observed a significant difference in FVIII according to the tumor site. In patients with tumor entities with known high risk of thrombosis, such as cancers of the stomach or pancreas, the highest factor VIII levels were found. An association between FVIII level and disease stage has been reported in patients with multiple myeloma. 16 We found such an association also in patients with solid cancer: Patients with metastasis had higher levels than those without. It is poorly understood to which extent the tumor contributes to FVIII plasma levels. Although the main site of FVIII synthesis is the liver, many other organs and cells are capable to produce FVIII. 9, 20 In vitro, it has been demonstrated that vascular endothelial growth factor (VEGF) induces FVIII expression by vascular endothelial cells. 21, 22 Solid tumors depend on neovascularization to grow larger, and VEGF plays a major role in the regulation of tumor angiogenesis. 23 However, the extent to which vascular endothelial cells contribute to FVIII plasma levels in cancer patients has not been clarified so far. As it is well known that FVIII is also an acute-phase protein, our study was designed to minimize possible influence of this origin. Patients with overt infection were not eligible for inclusion in the study. In multiple myeloma patients a strong increase of FVIII levels during chemotherapy was reported. 24 To avoid a treatment related bias of FVIII measurement, we excluded patients with chemotherapy within the last 3 months before inclusion. Recent investigations show that low-density lipoprotein receptor-related protein-1 (LRP-1) and polymorphisms of its gene are important for the regulation of FVIII plasma levels. 25, 26 LRP-1 expression of cancer cells may have im-portant implication for tumor metastasis. 27 These mechanisms need to be further elucidated.
Reports about the thrombosis risk according to FVIII in cancer patients are rare. Our data showing the increased risk for VTE in patients with elevated FVIII are in accordance with a former small retrospective study that reported higher FVIII levels in cancer patients with thrombosis. Another recent prospective study in 135 multiple myeloma patients and 124 age-and sex-matched healthy controls found higher baseline factor VIII levels in patients compared to controls, but was not able to demonstrate an increased thrombosis risk. 16 Some limitations of this study need to be addressed. FVIII activity was measured only once at study inclusion. We cannot exclude that FVIII activity levels might have changed during the further course of disease and under consecutive treatments. In patients with spontaneous VTE, however, it has been shown that factor VIII levels stay stable over a considerable period of time and most events in our study were observed in the first months after study inclusion. 28 A significant prevalence of asymptomatic VTE has been reported in cancer patients. 29 We cannot exclude that asymptomatic VTE was present in some patients and impaired their course of disease and survival. Because autopsy protocols were not always available, fatal pulmonary embolism might have been overlooked in some cases. Venous thromboembolism is a multifactorial disease. Inclusion of more parameters of interest into the statistical analysis would have been desirable, and it is a limitation of our study that because of the relatively small number of events the number of investigated parameters had to be restricted. Inclusion of established thrombosis risk factors had highest priority.
Our results can best be applied to patients similar to those included in our study. Our study provides data of a large number of patients with different tumor sites that were followed over a considerable time period. We proved the association of FVIII with the VTE risk in a multivariable regression model that was adjusted for the treatment regimen. In the present study the majority of events occurred within the first months after enrollment; after 6 months of observation 14% of patients with elevated factor VIII had experienced VTE. Therefore, we think that determination of FVIII would be a valuable tool for risk stratification in cancer patients.
